Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques

Immunity, Inflammation and Disease

Volumn 3, Issue 2, 2015, Pages 82-93

  Borthwick, Nicola J ^a   Rosario, Maximillian ^a   Schiffner, Torben ^a   Bowles, Emma ^a   Ahmed, Tina ^a   Liljeström, Peter ^b   Stewart Jones, Guillaume E ^a   Drijfhout, Jan W ^c   Melief, Cornelis J M ^c   Hanke, Tomas ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; Conserved regions; HIV vaccines; Macaques; Synthetic long peptides

Indexed keywords

EID: 84963947646     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.52     Document Type: Article

References (48)

1. McMichael, A. J., and B. F. Haynes. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13:423–427.
2. McMichael, A. J., and W. C. Koff. 2014. Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat. Immunol. 15:319–322.
3. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:379–385.
4. + T cell responses. Eur. J. Immunol. 35:2532–2540.
5. Hanke, T. 2014. Conserved immunogens in prime-bost strategies for the next-generation HIV-1 vaccines. Expert Opin. Biol. Ther. 14:601–616.
6. Harari, A., F. Vallelian, and G. Pantaleo. 2004. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur. J. Immunol. 34:3525–3533.
7. + T cell responses with distinct clonotype and epitope specificity. J. Immunol. 183:2425– 2434.
8. Barouch, D. H., M. G. Pau, J. H. Custers, W. Koudstaal, S. Kostense, M. J. Havenga, et al. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290– 6297.
9. Bridgeman, A., Y. Roshorm, L. J. Lockett, Z.-Z. Xu, R. Hopkins, J. Shaw, et al. 2009. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28:474–483.
10. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, et al. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354–2360.
11. Fischer, W., S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, et al. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100–106.
12. Gao, F., B. T. Korber, E. Weaver, H. X. Liao, B. H. Hahn, and B. F. Haynes. 2004. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev. Vaccines 3: S161–S168.
13. Altfeld, M., M. M. Addo, E. S. Rosenberg, F. M. Hecht, P. K. Lee, M. Vogel, et al. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17:2581–2591.
14. Ferguson, A. L., J. K. Mann, S. Omarjee, T. Ndung’u, B. D. Walker, and A. K. Chakraborty. 2013. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 38:606–617.
15. Kelleher, A. D., C. Long, E. C. Holmes, R. L. Allen, J. Wilson, C. Conlon, et al. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375–386.
16. Leslie, A. J., K. J. Pfafferott, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, et al. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10:282– 289.
17. Letourneau, S., E.-J. Im, T. Mashishi, C. Brereton, A. Bridgeman, H. Yang, et al. 2007. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2:e984.
18. Frahm, N., P. Kiepiela, S. Adams, C. H. Linde, H. S. Hewitt, K. Sango, et al. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173–178.
19. + T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 81:3465–3476.
20. + T cell epitopes against virus challenges. PLoS Pathol. 7:e1002041.
21. Knudsen, M. L., A. Mbewe-Mvula, M. Rosario, D. X. Johansson, M. Kakoulidou, A. Bridgeman, et al. 2012. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to conventional plasmid DNA vaccine. J. Virol. 86:4082– 4090.
22. Ondondo, B., S. Abdul-Jawad, A. Bridgeman, and T. Hanke. 2014. Characterization of T-cell responses to conserved regions of the HIV-1 proteome in the BALB/c mice. Clin. Vaccine Immunol. 21:1565–1572.
23. Rosario, M., N. Borthwick, G. B. Stewart-Jones, A. Mbewe-Mwula, A. Bridgeman, S. Colloca, et al. 2012. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 26:275–284.
24. Rosario, M., A. Bridgeman, E. D. Quakkelaar, M. F. Quigley, B. J. Hill, M. L. Knudsen, et al. 2010. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40:1973–1984.
25. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intra-epithelial neoplasia. N. Engl. J. Med. 361:1838–1847.
26. Welters, M. J., G. G. Kenter, P. J. de Vos van Steenwijk, M. J. Lowik, D. M. Berends-van der Meer, F. Essahsah, et al. 2010. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. USA 107:11895–11899.
27. + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14:178–187.
28. Gottardo, R., R. T. Bailer, B. T. Korber, S. Gnanakaran, J. Phillips, X. Shen, et al. 2013. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE 8:e75665.
29. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275–1286.
30. Visciano, M. L., M. Tagliamonte, G. Stewart-Jones, L. Heyndrickx, G. Vanham, M. Jansson, et al. 2013. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. J. Trans. Med. 11:165.
31. Cavacini, L. A., C. L. Emes, A. V. Wisnewski, J. Power, G. Lewis, D. Montefiori, et al. 1998. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retro. 14:1271–1280.
32. Kunert, R., F. Ruker, and H. Katinger. 1998. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. Hum. Retro. 14:1115–1128.
33. Wu, X., Z. Y. Yang, Y. Li, C. M. Hogerkorp, W. R. Schief, M. S. Seaman, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856–861.
34. Huang, J., G. Ofek, L. Laub, M. K. Louder, N. A. Doria-Rose, N. S. Longo, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406– 412.
35. Menzies, S. L., V. Kadwad, L. C. Pawloski, T. L. Lin, A. L. Baughman, M. Martin, et al. 2009. Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Borde-tella pertussis infection. Clin. Vaccine Immunol. 16:1781– 1788.
36. Cavacini, L. A., J. E. Peterson, E. Nappi, M. Duval, R. Goldstein, K. Mayer, et al. 1999. Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals. J. Virol. 73:9638–9641.
37. Spentzou, A., P. Bergin, D. Gill, H. Cheeseman, A. Ashraf, H. Kaltsidis, et al. 2010. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 201:720–729.
38. van’t Wout A. B., H. Schuitemaker, and N. A. Kootstra. 2008. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat. Protoc. 3:363–370.
39. + T-cell decline in HIV-1 infection. J. Infect. Dis. 206:552–561.
40. Sarzotti-Kelsoe, M., X. Daniell, C. A. Todd, M. Bilska, A. Martelli, C. Labranche, et al. 2014. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J. Immunol. Methods. 409:147–160.
41. Zhou, T., I. Georgiev, X. Wu, Z. Y. Yang, K. Dai, A. Finzi, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811–817.
42. Koopman, G., N. Beenhakker, I. Nieuwenhuis, G. Doxiadis, P. Mooij, J. W. Drijfhout, et al. 2013. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 27: e95103.
43. Herrera, S., A. Bonelo, B. L. Perlaza, A. Z. Valencia, C. Cifuentes, S. Hurtado, et al. 2004. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int. J. Parasitol. 34:1535–1546.
44. Vambutas, A., J. DeVoti, M. Nouri, J. W. Drijfhout, G. B. Lipford, V. R. Bonagura, et al. 2005. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23:5271–5280.
45. Sabbatini, P., T. Tsuji, L. Ferran, E. Ritter, C. Sedrak, K. Tuballes, et al. 2012. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18:6497–6508.
46. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705–711.
47. Weiss, C. D. 2003. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev. 5:214–221.
48. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209–2220.